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Abstract
Cyclin-dependent kinases (CDKs) play important roles in regulating cell cycle progression, and altered cell cycles resulting
from over-expression or abnormal activation of CDKs observed in many human cancers. As a result, CDKs have become
extensive studied targets for developing chemical inhibitors for cancer therapies; however, protein kinases share a highly
conserved ATP binding pocket at which most chemical inhibitors bind, therefore, a major challenge in developing kinase
inhibitors is achieving target selectivity. To identify cell growth inhibitors with potential applications in cancer therapy, we
used an integrated approach that combines one-pot chemical synthesis in a combinatorial manner to generate diversified
small molecules with new chemical scaffolds coupled with growth inhibition assay using developing zebrafish embryos. We
report the successful identification of a novel lead compound that displays selective inhibitory effects on CDK2 activity,
cancer cell proliferation, and tumor progression in vivo. Our approaches should have general applications in developing cell
proliferation inhibitors using an efficient combinatorial chemical genetic method and integrated biological assays. The novel
cell growth inhibitor we identified should have potential as a cancer therapeutic agent.
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Introduction
Cancer cell proliferation resembles normal embryonic growth in
a way that both are extremely rapid. In zebrafish, a single cell
zygote develops into an organism possessing essentially all organ
rudiments of a vertebrate species in 24 hours. To achieve rapid
cell growth, both developing embryonic cells and cancel cells use a
strategy in which G1 and G2 phases of cell cycles are shortened or
eliminated. Cyclin-dependent kinases (CDKs) play key roles in
regulating cell cycle progression and their abnormal activation
frequently associates with human cancers. CDKs are serine/
threonine kinases that activate host proteins through phosphory-
lation on serine or threonine using adenosine triphosphate (ATP)
as a phosphate donor. The activity of each CDK depends on the
binding of a cognate cyclin[1,2]. Although CDKs are continuously
expressed, the concentration of cyclins are regulated by the cell
cycle-dependent synthesis and ubiquitin-mediated degradation
during the cell cycle[3–5]. The oscillation of CDK activities
regulates cell cycle progression in response to a wide array of cell
signaling pathways.
Altered cell cycles resulting from abnormal levels or activation
of cyclins and CDKs occur frequently in human cancers[6]. Over-
expression of cyclin E is observed in many human cancers
including breast, brain, endometrial, and lung cancers, as well as
lymphomas and leukemias[7–9]. The cyclin D1 gene is amplified
in 15% of breast cancers and up-regulation of cyclin D1 is
associated with large fractions of breast, ovarian, and other
cancers[10,11]. Abnormal activation of cyclin A is found in human
hepatocarcinomas[12]. CDK2 normally associates with cyclin E
or cyclin A and serves as a key regulator for the G1 and S phase
progression[6] while CDK4 or CDK6 regulates G1 progression by
interacting with cyclin D. The CDK2-cyclin E complex primarily
regulates the G1 to S phase transition[13–15] whereas CDK2-
cyclin A promotes S phase progression and drives its comple-
tion[16]. As CDKs are critically involved in regulating the cell
cycle and their abnormal activities contribute to tumor genesis,
often through interaction with pathways regulated by oncogenes
and tumor suppressors, they have become valid targets for
developing chemical inhibitors for cancer therapies[17–19].
To date, several small molecules that inhibit CDK2 activities
have been identified[20–23]. Most of them induce cell cycle arrest
at G1 phase, leading to either the inhibition of cell proliferation or
induction of apoptosis in tumor cells. Several reports also showed
that cells could be arrested at G2/M phases when treated with
CDK2 inhibitors. Most encouragingly, some of these agents have
been shown to induce tumor regression in vivo without significant
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4361toxicity to normal organisms[24]. Despite these findings, it is
generally accepted that combinatory usage of inhibitors against
various CDKs may be needed to fully block cancer proliferation
since potential redundancy of CDK functions in the cell cycle may
limit the effects of selective CDK inhibition. Therefore, it is highly
desirable to expand the repertoires of new methods and screening
strategies for rapidly synthesizing combinatorial chemicals and
efficiently identifying active small molecular inhibitors for various
CDKs.
Protein kinases share a highly conserved ATP binding pocket at
which the majority of chemical inhibitors bind. Therefore, a major
challenge in developing kinase inhibitors is achieving target
selectivity. A critical factor towards selectivity is the development
of synthetic methods that allow for the creation of focused
chemical libraries with greater structure diversity. Diversity is an
important parameter because it enables the identification of
selective inhibitors across a panel of different kinases and
simultaneously provides structure-activity information. By further
improving chemical structures coupled with activity assays, this
should facilitate the discovery and development of potent yet
selective inhibitors for a desired class of protein kinases.
In connection with our development of a chemical genetic
approach to analyzing biological systems by using interfacing
libraries of small molecules followed by validating biological
assays[25], we developed a highly efficient one-pot-synthesis[26–
28] via a multi-components reaction[29–32] to generate focused
chemical libraries. More importantly, we coupled the chemical
approach to the whole zebrafish embryonic assay to rapidly select
active molecules that inhibit growth and induce cell cycle arrest.
Zebrafish embryos are externally accessible and their developmental
growth is extremely rapid, reminiscent of tumor progression except
ina highly controlled fashion.The simpledevelopmental retardation
assay of embryonic growth followed by determining stage of cell
cycle arrest and apoptosis makes it possible to quickly identify
inhibitorsspecifictocellcyclephases.Additionally,thissystemallows
selection of less toxic compounds that do not cause necrosis of whole
embryonic body. Further studies using chemical bioinformatics and
biochemical assays suggested that the lead compound selected by
zebrafish assay had a higher specificity to CDK2 kinase inhibition
and it also reduced tumor cell proliferation in vivo without significant
toxicity to xenograft mouse hosts.
Results
Computational design of CDK inhibitors
To date, most kinase inhibitors target the ATP-binding site.
However, the ATP-binding pockets of 518 human kinases
discovered so far are very similar to each other, especially for
those kinases of the same superfamily or subfamily such as CDKs.
The identification and synthesis of selective small-molecule kinase
inhibitors was therefore regarded as a challenge and has been an
active topic. Several kinase inhibitors have been identified,
including staurosporine (3) and indirubin-5-sulfonic acid (4)
(Figure 1A). These inhibitors can inhibit various CDKs by
targeting the ATP binding pocket of CDKs, which is located in
the deep cleft formed by N-lobe, C-lobe, and the hinge region in
CDKs[1,33]. Despite striking chemical diversity [34–36], those
CDK inhibitors share several common features: (1) they act by
competing with ATP for binding in the ATP-binding site; (2) they
are flat, hydrophobic heterocycles; and (3) they bind mostly by
hydrophobic interactions and hydrogen bonds with kinases. As a
result, the cross-reactivity of these kinase inhibitors to a spectrum
of other kinases prohibits their utilities as specific CDK inhibitors
for cancer therapy.
To develop more specific CDK inhibitors, we focused our
computational design on the common structural properties of
these kinase inhibitors and the structural features of the ATP
binding pocket of CDKs. Almost all of the CDK inhibitors form
hydrogen bonds with the hinge region of CDKs, so we set this as
the primary criteria to evaluate many known and our virtually
designed scaffolds on the crystal structure of CDK2[37] (PDB
code: 1OI9) using docking software, AutoDock3.0 (Figure 1B)[38].
Our examination revealed that a novel scaffold (5) in Figure 1C
might potentially bind to CDK2 with high affinity (Estimated
binding free energy DG,8.6 kcal/mol). This scaffold satisfies the
hydrogen bond criteria, and also has other common structural
features of reported CDK inhibitors, like a planar hydrophobic
heterocyclic framework, which fits well with the ATP binding cleft
through favorable van der Waals and hydrophobic contacts. This
scaffold has not been previously used for CDK2 inhibition and
may provide a new scaffold for CDK inhibition. These quinoline-
based poly-heterocycle scaffolds were further diversified and
examined for potential high affinity and selectivity for CDK2.
One of them, scaffold 6 (Figure 1C), can be designed with the
intention of providing an additional phenolic group at the D ring
to add the third hydrogen bond with the carbonyl group of Glu81.
The binding model of this particular scaffold is similar to that of
Flavopiridol (Figure 1A), an experimental drug currently in clinic
trials, with an additional hydrogen bond between the N-H group
of the lactam and carbonyl group of Leu83. Thus, the relatively
small and novel structures of the quinoline-based poly-heterocycles
provide a wide array of structural diversity for developing new
specific CDK inhibitors. With these considerations, we synthesized
a series of chemical compounds.
Synthesis
To date, many heterocyclic scaffolds have been developed as
kinase inhibitors[39–42], and each scaffold presents unique
opportunities for the presentation of functional groups to the
kinase active site. However, synthesis of those compounds usually
requires lengthy synthetic routes with overall low yields, which
prevents the syntheses of their structurally diverse analogs
efficiently, and limits the feasibility to achieve the molecular
libraries with discriminative binding to CDKs. To profile the
kinase inhibitors covering the entire human kinome, there is a
need to develop efficient and flexible methods for preparing novel
and structural diverse of molecular libraries.
For the synthesis of our proposed novel scaffold 5, we intended
to apply bienayme ´’s three-component reaction[43] of 2-amino-
pyrimidine 7, isonitrile 8, and aldehyde 9 to generate compound
12 through intermediates 10 and 11 (Figure 1D), which without
purification could undergo the TFA-mediated intramolecular
amide formation to afford quinoline-based tetracycle core,
realizing a post-transformation strategy to quickly access 5 via a
one-pot procedure[26–28].
Based on this highly efficient route, six different classes (24
compounds) of quinoline-based tetracycles were made from the
commercially available or synthetically accessible materials
(Figure 1E)[44]. Among them, scaffold 13-1 was predicted to
have the highest affinity to CDK2 ATP-binding pocket;
compounds bearing scaffold 13-2 to 17 were also synthesized to
test our prediction model and to deduce the structure-activity
relationship.
Identifying growth inhibitors with selectivity to CDK2
Zebrafish embryos develop extremely rapidly and are highly
accessible for direct microscopic observation. Several previous
studies have taken such advantages of zebrafish and established
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specific chemical compound activities[45,46]. Using zebrafish
embryos one can visually examine desirable activity as well as
toxicity of a compound. During early development, cell prolifer-
ation is very active and cells can complete the entire cycles in
ranges of minutes[47]. We reasoned that if a compound can
inhibit rapid growth of a zebrafish embryo, it would likely inhibit
other rapid cell growth such as uncontrolled proliferation of cancer
cells. In addition, since we can easily obtain primary cells from live
embryos it is relatively straightforward to determine at which
particular stage the cells are arrested, such as G1 or G2 phase.
The 24 compounds described above were screened against
zebrafish embryos and several compounds were shown to delay
embryonic development without causing drastic change of body
structure at concentrations of micromoles (Figure 2B). Three
compounds (13-1-a, 13-1-e and 13-1-f) were selected for further
studies due to their high potency (Figure 2A). To validate the
zebrafish assay, we performed an independent cell proliferation
assay by treating breast cancer cell line MDA-MB-231 with
various concentrations of our chemical library. We found that all
the compounds that delayed zebrafish embryonic development
also inhibited cell proliferation, although the rank of potency for
Figure 1. Structures, binding models and syntheses of CDKs inhibitors. (A) CDKs inhibitors and their bonding modes. (B) Docking of scaffold
6 with the crystal structure of CDK2 (PDB code: 1OI9) (docking software: AutoDock3.0). (C) Representative scaffolds (5 and 6) in docking. (D) Proposed
one-pot synthesis of compound 5. (E) Synthesized quinoline-based polyheterocycles.
doi:10.1371/journal.pone.0004361.g001
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PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e4361Figure 2. Representative active compounds and resulted phenotypes. (A) Representative active compounds. Compounds 13-1-a, 13-1-e and
13-1-f are the most potent in zebrafish assay with the lowest effective concentration below 10 mM. (B) Embryonic phenotypes of compound
treatment. a) control (10 hpf), b) control (24 hpf); c–e) show embryos treated with 20 mmol/L of 13-1-a (c), 13-1-e (d), and 13-1-f (e) and observed at
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both assays, compound 13-1-e remained as the top candidate. We
therefore performed additional experiments to elucidate its mech-
anism of action and ability to inhibit tumor growth in vivo.T o
determine if 13-1-e has affect on cell cycle we isolated primary cells
from the control and treated zebrafish embryos and analyzed cell
cycle progression by fluorescence activated cell sorting (FACS)
analysis. As shown in Figure S1, compound 13-1-e arrested the cell
cycle atG1phaseinadosedependentmanner(FigureS1,TableS1).
Several previous studies suggest that embryonic eye develop-
ment is indicative of cell cycle activity in zebrafish. Inhibition of
cyclin D1 protein translation in zebrafish by morpholino
knockdown caused more visible defects in embryonic eyes[48].
In situ hybridization data showed that expression of CDK2 appears
more in embryonic head[49], suggesting that inhibition of CDK2
will affect head structures more than other parts of the embryo.
Consistent with this hypothesis, embryos treated with 13-1-e
indeed had stronger phenotypes in brain and eyes of zebrafish
embryos (Figure 2C).
The candidate cell cycle inhibitors were further examined for
their ability to inhibit the kinase activity of purified cyclin E/
CDK2 using histone H1 as the substrate. Similar to the inhibitory
activity on zebrafish embryos and cell proliferation, our study
showed that 13-1-e has the highest potency of inhibiting the cyclin
E/CDK2 kinase activity, with IC50 between 1–2 mM, whereas
compound 13-1-a is moderate (IC50: about 100 mM) and
compound 13-1-f has no discernible effect (Figure 3A–C). Analysis
by computational docking and simulation indicated that while 13-
1-a can form two hydrogen bonds with leucine 83 (L83), 13-1-e
forms an additional hydrogen bond with the backbone of glutamic
acid 81 (E81) in CDK2. The enhanced inhibition of the kinase
activity of cyclin E/CDK2 by 13-1-e is thus likely due to the
formation of this additional hydrogen bond between the
compound and CDK2. This hypothesis is further confirmed by
the observation that 13-1-f has no obvious inhibitory activity to
CDK2, which is consistent with our modeling analysis that the
replacement of the hydroxyl group by the methoxy group of D
ring eliminates this additional hydrogen bond and causes slightly
steric interaction with the carbonyl oxygen of E81. To test whether
the hydrophobic interaction between the aromatic ring of 13-1-e
and Phe80 are critical for the specificity of CDK2 kinase
inhibition, we determined the inhibitory specificity of the 13-1-a
and 13-1-e towards ERK2, a member of MAP kinase family, also
a memberof CMGCsuperfamily,whichcontains a polar gatekeeper
residue glutamine (Q103) at corresponding positions of Phe80 in
CDK2. Our analysis indicated that neither 13-1-e nor 13-1-a has
significant inhibitory effect on the activity of ERK2 (Figure 3D),
although a slight effect was observed at high drug concentrations
(.100 mM). Finally, these compounds were profiled against a panel
of 21 kinases for inhibitory effect and 13-1-e was shown to have the
highest inhibition of CDK2 activity (Table S2).
To test if 13-1-e was able to inhibit tumor cell proliferation in vitro
and tumor size in vivo, two more experiments were carried out. First,
in cultured condition, 13-1-e was shown to inhibit proliferation of
mouse colon tumor cells CT26 with an IG50 of approximately
20 mM (Figure 4A). Second, in a xenograft tumor model, ten days
after subcutaneous injection of 3610
5 CT26 into the BalB/C mice,
12.5 mg/kg of 13-1-e was intraperitoneally administrated every
otherdayforeachmouse(N=5).AsshowninFigure4B,tumorsizes
were significantly smaller than those of controls injected with
dimethyl sulfoxide (DMSO) after 10 treatments. Under this condi-
tion, mice treated 13-1-e had no obvious detrimental phenotypes.
These studies established that 13-1-e has the ability to inhibit
cancerous cell growth both in vitro and in vivo.
Discussion
Our compound is likely inhibiting CDK as one of its major
targets, although other kinases may be involved. It has been shown
that CDKs are highly conserved proteins throughout the
evolution. In particular, zebrafish and human CDK2 proteins
are very similar to each other, with both of them having 298
amino acid residues and sharing about 90% identities of amino
acid residues. Figure 1E summarizes the chemical structures of
quinoline-based tetracycles used in the inhibition assay of zebrafish
embryonic growth. Analysis of the activities of these compounds
suggests that several compounds in 13-1 family, such as 13-1-a, 13-
1-e are all growth inhibitors. Among them 13-1-e shows the most
10 hpf (compounds were added at 5.5 hpf); f–h) show embryos at 24 hpf after the same treatment [13-1-a (f), 13-1-e (g), 13-1-f (h)]. Note smaller sizes
compared control. (C) Compound 13-1-e has stronger effect on brain and eye development of zebrafish embryos. a) control (24 hpf), b) 13-1-e
(20 mmol/L), c) 13-1-e (30 mmol/L), d) 13-1-e (40 mmol/L), 24 hpf; e) control (36 hpf), f) 13-1-e (20 mmol/L), g) 13-1-e (30 mmol/L), h) 13-1-e (40 mmol/
L), 36 hpf. Compounds were added at 5.5 hpf.
doi:10.1371/journal.pone.0004361.g002
Figure 3. Kinase Assays. (A) The effects of compounds on purified
recombinant CDK2/Cyclin E kinase activity to Histone H1; (B) The dose
effect of 13-1-e on CDK2/Cycin E kinase activity; (C) The Dose effect of
13-1-a on CDK2/Cyc E kinase activity; (D) The Effect of 13-1-a and 13-1-e
on the ERK2 kinase activity towards MBP.
doi:10.1371/journal.pone.0004361.g003
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inhibition of cyclin E/CDK2 kinase activity, and the prevention of
tumor cell proliferation in vitro and tumor size in vivo. These
observations areinagreement with the computational analysisof our
previous docking study, which indicates compound 13-1-e can fit the
adenine binding pocket well with three hydrogen bond sites. Other
quinoline-based tetracyclic scaffolds of series 13-2 to 17 are mostly
ineffective in the zebrafish embryonic assays. It is worth noting that
13-1-a and 13-1-f both are capable of inhibiting embryonic growth
but appear not effective for inhibiting CDK2. These compounds
may have different targets in vivo that regulate cell proliferation.
Although our lead compound is still less potent and selective
compared to some of the previously reported CDK2 inhibitors 13-
1-e and its derivatives represent a new scaffold for improvement.
This scaffold is a promising template for the rational design and
synthesis of novel kinase inhibitors. Considering their low
molecular weights, this chemical class will allow facile and broad
decoration with various substituents on their framework. With
such a high spatial potential of improving this scaffold it is possible
to generate more potent and selective CDK inhibitors by
exploiting additional interactions with residues that lie outside
the ATP binding cleft. As a potential candidate for cancer
therapies inhibition of excess cell proliferation without strong
toxicity will be the ultimate goal. Our study demonstrates the
utility of an integrated approach to rapidly identify novel scaffolds
that have activity of inhibiting cell proliferation. With this
approach, growth inhibition activity of any newly synthesized
compounds can be determined within 24 hours using living
zebrafish embryos. In the case of 13-1-e, although CDK2 may not
be the only target, it may have better potential to block cancerous
cell growth by targeting more than one kinase.
Our studies establish that zebrafish embryo assay can be used to
rapidly screen for cell cycle and proliferation inhibitors. This assay,
coupled with new chemical synthesis, computational, biochemical
and mammalian analysis, allows the identification of specific small
molecules that inhibit specific kinase such as CDK2. The
compound we identified inhibits zebrafish embryo growth at a
specific cell cycle phase, reduces mammalian CDK2 activity as
well as tumor cell proliferation in vitro and in vivo. Since we only
select those compounds that retard embryonic growth but not
induce gross abnormality of embryonic body and tissues, they may
have less toxicity in further preclinical studies. The zebrafish
model for identifying kinase inhibitors should have even broader
applications. The recent study by Lemeer et al. suggests that a large
number of protein kinase activities in developing embryos can be
profiled using arrays of multiple standard peptide substances,
suggesting a wide conservation of kinases between human and
zebrafish[50]. With direct analysis of zebrafish embryos treated
with a specific small molecule, it should be possible to determine its
potency and specificity through phenotypic determination coupled
with profiling a panel of representative kinases.
Materials and Methods
Synthetic protocols
Reference [44].
Chemical treatment
Embryo treatments were done from 5.5 hours post fertilization
(hpf) until 24 hpf in Holtfreter’s buffer with 1% DMSO at 28.5uC.
Cell line testing of compounds was performed in medium with
0.3% DMSO at 37uC. Holtfreter’s Solution: NaCl 3.5 g,
NaHCO3 0.2 g, KCl 0.05 g, MgSO4 stock solution 333 ml, CaCl2
stock solution 333 ml, add ddH2O 1 liter (MgSO4 stock solution:
MgSO4 300 g in 500 ml ddH2O; CaCl2 stock solution: CaCl2
150 g in 500 ml ddH2O), adjust pH to 7.3.
Screen methods
The primary screen was carried out in 96-well-plates. 2 mLo f
each compound (2.5 mg/mL in DMSO) was diluted to a total
volume of 200 mL with Holtfreter’s buffer. The average concen-
tration of each small molecule was about 100 mM. Embryos are
distributed to 96-well-plates with three embryos placed in each
well. Then diluted solution of each compound was added.
Embryos were exposed to compound solution and incubated at
Figure 4. In vivo anti-tumor activity. (A) Compound 13-1-e inhibits proliferation of mouse colon tumor cell line CT26 in vitro. The number of cells
treated with 0.3% DMSO serves as the control here. Red fluorescence represents the nuclei revealed by PI staining. (B) Average tumor size of CT26
cells injected in five mice followed by injections of ten doses of DMSO (50 ml) or 13-1-e (dissolved in 50 ml DMSO, 12.5 mg/kg for every two days) are
821 (6345) mm
3 (DMSO) and 510 (6107) mm
3 (13-1-e). P,0.05.
doi:10.1371/journal.pone.0004361.g004
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two times at 12 hpf and 24 hpf separately. Once active compounds
were identified, each one was analyzed at 100, 40, 30, 20, 10, 4, 2,
and 0.4 mM to determine its lowest effective concentration.
Image acquisition and analysis
For general examination, GFP-positive embryos or larvae were
viewed under an Axioimager Z1 fluorescence microscope (Zeiss),
equipped with 5, 10 and 206objectives.
DNA content analysis
Dechorionated embryos were disaggregated on ice in 16PBS
and serially passed through 105- and 40-mm filters. Cells were
washed in ice-cold 16PBS and stained with propidium iodine.
Fluorescence-activated cell sorter (FACS) analysis was done on a
BD FACSCalibur flow cytometry (Becton Dickinson, Franklin
Lakes, NJ, USA) and analyzed using CellQuest.
Kinase assays
The CDK2/GST-Cyclin E kinase complex was produced in
baculovirus expression system. The purified kinase (100 ng) was
mixed with 2 mg histone H1(Upstate), 4 ml of 56 kinase
buffer(100 mM Tris, pH 7.4, 50 mM MgCl2, 2.5 mM DTT),
0.5 mCi gamma-
32P-ATP, the indicated amount of chemicals and
water to a final volume of 20 ml. The mixtures were incubated at
30uC for 30 min and then loaded to an SDS-PAGE and the
labeled histone H1 was separated by electrophoresis and visualized
by autoradiography. The HA-tagged ERK2 was expressed in 293
cells after transfection and the kinase was immunoprecipitated
with anti-HA antibody/protein A Sepharose beads. The beads
were assayed for Erk2 kinase activity in the presence or absence of
chemicals as conducted in CDK assays, except 2 mg MBP (Sigma)
were used instead of histone H1. Inhibition profile assay against a
panel of 21 kinases was carried out by a commercial service with a
fluorescence assay using 5 mM of each compound.
Determination of GI50 in cultured cells
MDA-MB-231 or CT26 cells were plated at a density of 2000
cells/well in a 96-well plate. Drugs were added after 24 h and
serial diluted (4, 7.5, 15, 20, 40, 80, 150 mM). The cells were
incubated with the compounds at 37uC for 72 h, and then the cell
number was measured.
In vivo anti-tumor activity
3610
5 CT26 cells were subcutaneously injected into the right
flank of 6–8 weeks old BalB/C female mice. When tumors were
palpatable at 11 days after inoculation (4–6 mm in diameter), mice
were divided into five groups (N=5 for each group). These mice
were given intraperitoneally with 50 ml PBS, 50 ml DMSO, or
each chemical compounds dissolved in 50 ml DMSO, respectively.
Reagents [12.5 mg/kg; total 50 ml] were given every 2 days for 20
days. Tumor size was determined by caliper measurement of the
largest and perpendicular diameters and volumes were calculated
according to the formula: tumor volume (mm
3)=0.526length
(mm)6width (mm)6width (mm).
Supporting Information
Figure S1 Cell cycle analysis of embryos treated with 13-1-e
40 mmol/L compound 13-1-e could arrest cell cycle at G1 phase
in zebrafish embryos compare with 1%DMSO control. Embryos
were treated with compound from 7 hpf, after exposed to
compounds for 3 hours, embryos were manipulated to do the
FACS analysis.
Found at: doi:10.1371/journal.pone.0004361.s001 (1.53 MB TIF)
Table S1 The cell cycle phase changes depend on concentra-
tions of 13-1-e Embryos were treated with deferent concentrations
of 13-1-e since 7 hpf; after exposed to compounds for 3 hours,
embryos were manipulated to do the FACS analysis. (Based on
three independent experiments)
Found at: doi:10.1371/journal.pone.0004361.s002 (0.03 MB
DOC)
Table S2 Inhibition of individual kinases by three selected
compounds Each compound (5 mM) was added to individual
kinase and activity was compared to control activity without
compounds. Numbers indicate % of inhibition. Note that 13-1-e
inhibited CDK2 by 45%, which is the highest among the 21
kinases. Interestingly, the compounds appear to stimulate activities
of some kinases.
Found at: doi:10.1371/journal.pone.0004361.s003 (0.05 MB
DOC)
Acknowledgments
We thank Ms. Liying Du for the help in Flow Cytometry operation and
data analysis. We appreciate Mr. Shengchang Xin and Mr. Wei Liang for
help in experiment and discussion.
Author Contributions
Conceived and designed the experiments: JX HY CC JQ HZ ZY SL.
Performed the experiments: JX HY CC HZ HY. Analyzed the data: JX
HY HZ JC BZ YW JQ HZ ZY SL. Contributed reagents/materials/
analysis tools: HY JC BZ YW JQ HZ. Wrote the paper: JX JQ HZ ZY SL.
References
1. Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and micropro-
cessors. Annu Rev Cell Dev Biol 13: 261–291.
2. Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and
checkpoint control. J Clin Invest 104: 1645–1653.
3. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677.
4. Pavletich NP (1999) Mechanisms of cyclin-dependent kinase regulation:
structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol
Biol 287: 821–828.
5. Koepp DM, Harper JW, Elledge SJ (1999) How the cyclin became a cyclin:
regulated proteolysis in the cell cycle. Cell 97: 431–434.
6. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in
cancer. Nat Rev Cancer 1: 222–231.
7. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS (1999)
Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and
precedes squamous cell carcinoma development. Cancer Res 59: 2470–2476.
8. Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, et al. (2003)
Immunohistochemical expression of cyclin E in endometrial adenocarcinoma
(endometrioid type) and its clinicopathological significance. J Cancer Res Clin
Oncol 129: 222–226.
9. Wolowiec D, Benchaib M, Pernas P, Deviller P, Souchier C, et al. (1995)
Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias.
Comparison with non-Hodgkin’s lymphomas and non-neoplastic lymphoid
tissue. Leukemia 9: 1382–1388.
10. Fantl V, Smith R, Brookes S, Dickson C, Peters G (1993) Chromosome 11q13
abnormalities in human breast cancer. Cancer Surv 18: 77–94.
11. Malumbres M, Barbacid M (2007) Cell cycle kinases in cancer. Curr Opin
Genet Dev 17: 60–65.
12. Wang J, Chenivesse X, Henglein B, Brechot C (1990) Hepatitis B virus
integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343:
555–557.
13. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12:
2245–2262.
14. Zheng L, Lee WH (2001) The retinoblastoma gene: a prototypic and
multifunctional tumor suppressor. Exp Cell Res 264: 2–18.
Cell Growth Inhibitors
PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e436115. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, et al. (2000) Survivin
initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a)
and Cdk2/cyclin E complex activation. Oncogene 19: 3225–3234.
16. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992) Cyclin A is
required at two points in the human cell cycle. Embo J 11: 961–971.
17. Fischer PM, Lane DP (2000) Inhibitors of cyclin-dependent kinases as anti-
cancer therapeutics. Curr Med Chem 7: 1213–1245.
18. Sielecki TM, Boylan JF, Benfield PA, Trainor GL (2000) Cyclin-dependent
kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 43: 1–18.
19. Meijer L, Leclerc S, Leost M (1999) Properties and potential-applications of
chemical inhibitors of cyclin-dependent kinases. Pharmacol Ther 82: 279–284.
20. Byth KF, Cooper N, Culshaw JD, Heaton DW, Oakes SE, et al. (2004)
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent
kinase inhibitors. Bioorg Med Chem Lett 14: 2249–2252.
21. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, et al. (2004) 3-
Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead
finding. J Med Chem 47: 3367–3380.
22. Tang J, Shewchuk LM, Sato H, Hasegawa M, Washio Y, et al. (2003)
Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological
evaluation, and X-ray crystallographic analysis. Bioorg Med Chem Lett 13:
2985–2988.
23. Luk KC, Simcox ME, Schutt A, Rowan K, Thompson T, et al. (2004) A new
series of potent oxindole inhibitors of CDK2. Bioorg Med Chem Lett 14:
913–917.
24. Hirai H, Kawanishi N, Iwasawa Y (2005) Recent advances in the development
of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top
Med Chem 5: 167–179.
25. Sumanas S, Lin S (2004) Target. Elsevier Ltd.
26. Koeller KM, Wong CH (2000) Synthesis of complex carbohydrates and
glycoconjugates: enzyme-based and programmable one-pot strategies. Chem
Rev 100: 4465–4494.
27. Nicolaou KC, Montagnon T, Snyder SA (2003) Tandem reactions, cascade
sequences, and biomimetic strategies in total synthesis. Chem Commun (Camb).
pp 551–564.
28. Balme G, Bossharth E, Monteiro N (2003) Pd-assisted multicomponent synthesis
of heterocycles. European Journal of Organic Chemistry. pp 4101–4111.
29. Armstrong RW, Combs AP, Tempest PA, Brown SD, Keating TA (1996)
Multiple-component condensation strategies for combinatorial library synthesis.
Accounts of Chemical Research 29: 123–131.
30. Domling A, Ugi II (2000) Multicomponent Reactions with Isocyanides. Angew
Chem Int Ed Engl 39: 3168–3210.
31. Bienayme H, Hulme C, Oddon G, Schmitt P (2000) Maximizing synthetic
efficiency: Multi-component transformations lead the way. Chemistry-a
European Journal 6: 3321–3329.
32. Zhu JP (2003) Recent developments in the isonitrile-based multicomponent
synthesis of heterocycles. European Journal of Organic Chemistry. pp
1133–1144.
33. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, et al. (1993)
Crystal structure of cyclin-dependent kinase 2. Nature 363: 595–602.
34. Sharma V, Lansdell TA, Jin G, Tepe JJ (2004) Inhibition of cytokine production
by hymenialdisine derivatives. J Med Chem 47: 3700–3703.
35. Cantrell CL, Groweiss A, Gustafson KR, Boyd MR (1999) A new staurosporine
analog from the prosobranch mollusk Coriocella nigra. Natural Product Letters
14: 39–46.
36. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E,
et al. (2004) Structural basis for the synthesis of indirubins as potent and selective
inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med
Chem 47: 935–946.
37. Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, et al. (2004) N2-
substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-
dependent kinases 1 and 2. J Med Chem 47: 3710–3722.
38. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998)
Automated docking using a Lamarckian genetic algorithm and an empirical
binding free energy function. Journal of Computational Chemistry 19:
1639–1662.
39. Adams JL, Lee D (1999) Recent progress towards the identification of selective
inhibitors of serine/threonine protein kinases. Curr Opin Drug Discovery Dev 2:
96–109.
40. McMahon G, Sun L, Liang C, Tang C (1998) Protein kinase inhibitors:
structural determinants for target specificity. Curr Opin Drug Discovery Dev 1:
131–146.
41. Cohen P (1999) The development and therapeutic potential of protein kinase
inhibitors. Curr Opin Chem Biol 3: 459–465.
42. Huwe A, Mazitschek R, Giannis A (2003) Small molecules as inhibitors of cyclin-
dependent kinases. Angew Chem Int Ed Engl 42: 2122–2138.
43. Bienayme H, Bouzid K (1998) A new heterocyclic multicomponent reaction for
the combinatorial synthesis of fused 3-aminoimidazoles. Angewandte Chemie-
International Edition 37: 2234–2237.
44. Che C, Xiang J, Wang GX, Fathi R, Quan JM, et al. (2007) One-Pot Synthesis
of Quinoline-Based Tetracycles by a Tandem Three-Component Reaction.
J Comb Chem.
45. Peterson RT, Link BA, Dowling JE, Schreiber SL (2000) Small molecule
developmental screens reveal the logic and timing of vertebrate development.
Proc Natl Acad Sci U S A 97: 12965–12969.
46. Stern HM, Murphey RD, Shepard JL, Amatruda JF, Straub CT, et al. (2005)
Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat
Chem Biol 1: 366–370.
47. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF (1995) Stages
of embryonic development of the zebrafish. Dev Dyn 203: 253–310.
48. Duffy KT, McAleer MF, Davidson WR, Kari L, Kari C, et al. (2005)
Coordinate control of cell cycle regulatory genes in zebrafish development tested
by cyclin D1 knockdown with morpholino phosphorodiamidates and hydro-
xyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res 33: 4914–4921.
49. Thisse B, Thisse C [http://zfin.org/ expression pattern search result for cdk2]
(2007).
50. Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, et al. (2007) Protein-
tyrosine kinase activity profiling in knock down zebrafish embryos. PLoS ONE
2: e581.
Cell Growth Inhibitors
PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4361